November 8, 2026:


Arrowhead Pharmaceuticals is delivering one of the most closely watched presentations at this year’s American Heart Association Scientific Sessions in Chicago today, as cardiologist Luke Laffin, M.D., of the Cleveland Clinic presents the first complete clinical dataset for ARO-DIMER-PA — an experimental drug that does something no approved or investigational therapy has ever done: silence two distinct disease-causing genes using a single RNA interference (RNAi) molecule in the same injection.
The session — FS.05: Featured Science Session on Novel Lipid Lowering Therapies — kicks off at 3:15 p.m. CT in Learning Studio 2 of the South Hall at McCormick Place. It runs until 4:30 p.m. CT and also includes a pivotal pooled analysis from the SHASTA-3 and SHASTA-4 Phase 3 trials of plozasiran (REDEMPLO), Arrowhead’s already-approved RNAi drug for a related lipid disorder, to be presented by Christie Ballantyne, M.D., of Baylor College of Medicine and Houston Methodist.
Together, the two presentations represent what may be the broadest single-day RNAi cardiovascular showcase in medical conference history.
This is not a first glimpse. In a September 15, 2026 press release, Arrowhead disclosed interim topline data from the single-dose cohorts of its Phase 1/2a study (ARO-DIMER-PA-1001 trial registry), confirming that the drug had already delivered headline-level results:
“Mixed hyperlipidemia is not adequately addressed by treating LDL-C alone,” said Steven Nissen, M.D., of the Cleveland Clinic in Nissen commentary on HCPLive. He called ARO-DIMER-PA “a new approach to targeting multiple lipid abnormalities with a single therapy.”
What today’s AHA presentation adds is what the September topline figures could not: data from the multiple-dose cohorts (Part 2 of the study), the full pharmacokinetic and pharmacodynamic profile, the complete safety assessment across all dose levels, and a formal peer-reviewed debut before the cardiology community. The study is a randomized, double-blind, placebo-controlled, dose-escalation design enrolling up to 78 adults with mixed hyperlipidemia. Part 1 (single ascending doses through 400 mg) is complete; Part 2 (multiple dosing) is ongoing, and results from those cohorts are expected to be central to Laffin’s presentation.
The key to understanding ARO-DIMER-PA is Arrowhead’s Arrowhead TRiM platform description, specifically its “dimer” variant — a molecular architecture no approved drug uses.
Conventional RNAi drugs carry a single short-interfering RNA (siRNA) sequence that silences one gene. Inclisiran (Leqvio), approved in 2021, silences PCSK9 alone. Plozasiran (REDEMPLO), approved in late 2025, silences APOC3 alone. Each drug does its job well — but they are separate prescriptions, separate injections, and separate insurance negotiations.
ARO-DIMER-PA links two siRNA sequences together in one molecular construct — a dimer — with each arm targeting a different messenger RNA. Both arms travel to the liver on the same delivery vehicle: GalNAc (N-acetylgalactosamine), a sugar molecule that binds to the asialoglycoprotein receptor ASGPR expressed densely on hepatocytes (liver cells). One subcutaneous injection, one receptor-mediated uptake event, one round of endosomal escape — and two independent gene-silencing programs are activated inside the same cell.
Once in the cytoplasm, each arm of the dimer separately loads into a RISC (RNA-Induced Silencing Complex) with Argonaute 2 (Ago2). The PCSK9-targeting arm directs Ago2 to cleave PCSK9 messenger RNA → PCSK9 protein production falls → LDL receptors on hepatocytes are no longer degraded → more LDL-C is cleared from the blood. Simultaneously, the APOC3-targeting arm directs Ago2 to cleave APOC3 mRNA → APOC3 protein falls → lipoprotein lipase (LPL) is released from inhibition → triglyceride-rich lipoproteins are cleared more efficiently from the bloodstream.
It is worth noting what validating two-arm siRNA delivery also implies: the architecture is in principle scalable. If two siRNA arms can share a GalNAc delivery vehicle and independently activate RISC without interfering with each other, the ceiling on payload complexity is higher than approved drugs have yet demonstrated. Triple-functional or more elaborate multi-gene RNAi constructs targeting disease pathways driven by three or more genes simultaneously — PCSK9 plus APOC3 plus ANGPTL3, for example — become a rational next step, not a theoretical curiosity.
Approximately 21% of US adults — an estimated 42 million people — carry both elevated LDL-C and elevated triglycerides simultaneously, a condition known as mixed hyperlipidemia. This population sits in a treatment gap that has frustrated cardiologists for years.
Statins and even next-generation PCSK9-inhibiting drugs address the LDL side effectively. Achieving a 50 to 60% LDL-C reduction on PCSK9 inhibitor therapy, on top of a statin, is now routine for high-risk patients. But that achievement does not fully neutralize ASCVD (atherosclerotic cardiovascular disease) risk when triglycerides and triglyceride-rich lipoprotein remnants remain elevated. Mendelian randomization studies — which use naturally occurring genetic variants as proxies for drug effects — have established that simultaneous reductions in PCSK9 and APOC3 produce additive, not merely overlapping, coronary heart disease risk reductions. The two pathways are genuinely independent risk contributors.
The clinical landscape for attacking both simultaneously remains sparse. Inclisiran and evolocumab (Repatha) and alirocumab (Praluent) cover the PCSK9/LDL pathway. Olezarsen (Tryngolza) and plozasiran cover the APOC3/TG pathway. But all of these are separate drugs — and in July 2026, Merck’s oral PCSK9 inhibitor enlicitide decanoate received Lipfendra enlicitide FDA approval, adding a third PCSK9-targeting modality to a landscape that still has nothing combining both pathways in a single agent.
ARO-DIMER-PA would, if its efficacy holds in later-phase studies, fill that gap in a single quarterly or semi-annual injection — potentially achievable in a primary-care or pharmacy setting.
The same afternoon session will also feature something Arrowhead did not have even two years ago: Phase 3 results from a drug that is already on the market.
Plozasiran (branded REDEMPLO), an RNAi therapeutic targeting APOC3 alone, received approval in the United States, Canada, and China for familial chylomicronemia syndrome (FCS) — a rare, severe genetic disorder characterized by extreme triglyceride elevations and recurrent pancreatitis — in late 2025. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion in April 2026; Australia approved it in May 2026. For the broader indication of severe hypertriglyceridemia (sHTG), plozasiran received FDA Breakthrough Therapy designation in December 2025 and entered the FDA STAR pilot program in October 2026 in preparation for a supplemental NDA — it is not yet approved for sHTG.
Today’s AHA presentation from Christie Ballantyne, M.D., adds a pooled analysis of the pivotal SHASTA-3 (446 adults) and SHASTA-4 (391 adults) studies, which together randomized approximately 837 adults with sHTG (defined as fasting triglycerides ≥500 mg/dL) to plozasiran 25 mg subcutaneously once every three months (four doses over one year) or placebo.
Results first presented at the European Society of Cardiology (ESC) Congress in Munich in late August 2026 were striking. At Month 12, plozasiran reduced median triglyceride levels by 79% in SHASTA-3 and 81% in SHASTA-4, versus approximately 27% with placebo (p
The acute pancreatitis (AP) data carry the most clinical weight. A pre-planned pooled analysis found statistically significant reductions in both the proportion of patients experiencing at least one AP event (p
Ballantyne’s AHA presentation is expected to synthesize the SHASTA-3 and SHASTA-4 datasets in greater detail, potentially highlighting pancreatitis reduction across subgroups and offering a more granular view of plozasiran’s long-term tolerability profile as the company builds toward an sNDA submission.
Arrowhead is presenting additional plozasiran data at AHA 2026 in moderated digital poster sessions. At 9:15 a.m. CT, Robert Rosenson, M.D., of the Icahn School of Medicine at Mount Sinai will present a three-year efficacy and safety readout from the PALISADE study (plozasiran in FCS patients) and its open-label extension. At 1:45 p.m. CT, Daniel Gaudet, M.D., Ph.D., will present an analysis of how concurrent GLP-1 receptor agonist use — now among the most widely prescribed cardiometabolic drugs — affects triglyceride reductions achieved with plozasiran. The GLP-1 interaction data are clinically significant: the overlap between the severe hypertriglyceridemia population and GLP-1 users is substantial, and knowing whether the two drugs’ triglyceride-lowering effects are additive, redundant, or antagonistic has real prescribing implications.
Beyond lipids, the TRiM platform underpins Arrowhead’s pipeline across liver, lung, central nervous system, skeletal muscle, and adipose tissue targets. The company has an ongoing Phase 3 program for zodasiran in homozygous familial hypercholesterolemia (HoFH), and Phase 1/2 studies for ARO-INHBE and ARO-ALK7 targeting obesity. ARO-DIMER-PA represents a distinct branch of that expansion: demonstrating that the TRiM dimer architecture can reach clinical proof of concept opens a conceptual door to future multi-gene RNAi candidates for other complex diseases where single-target approaches leave residual risk on the table — not only in cardiology, but potentially in metabolic disease, inflammatory conditions, and any indication where two or more genes drive the same pathological pathway.
“The clinical validation of the dimer architecture potentially expands the number of diseases and patients worldwide that may be helped by Arrowhead’s RNAi therapies,” said Chris Anzalone, Arrowhead’s President and CEO.
The session begins at 3:15 p.m. CT. The ARO-DIMER-PA oral presentation from Luke Laffin, M.D., is expected within the first portion of the 75-minute session.
Key numbers to watch from the multiple-dose cohorts: While the September 2026 single-dose data already established LDL-C reductions (-54%) and TG reductions (-73%) as headline efficacy figures, today’s full presentation is expected to show how those reductions evolve with repeated quarterly dosing — specifically, whether the dual knockdown deepens, maintains, or slightly attenuates with multiple doses, and how long the lipid-lowering effect persists between injection cycles. The full pharmacokinetic profile will also characterize how the dimer is absorbed, distributed, metabolized, and eliminated differently from single-arm siRNA drugs.
Safety profile to watch: The clean early safety record (injection-site reactions and headache as the most common adverse events; no drug-related serious adverse events through 400 mg single doses) will be extended today to include the multiple-dose cohorts and the full dose range. Any signal of hepatotoxicity, platelet effects, or unexpected immunogenicity would be clinically meaningful at this stage.
Platform implications beyond lipids: If the first complete dataset is clean across both efficacy and safety dimensions, Arrowhead will likely use the AHA presentation and the company’s November 12 fiscal fourth-quarter earnings call — five days after today’s presentations — to outline the path for additional dimer programs. The more important scientific question behind the ARO-DIMER-PA data is not whether this specific drug will eventually be approved, but whether the two-arm siRNA architecture itself is robust enough to generalize. Today’s AHA session is the first clinical answer to that question.
The ARO-DIMER-PA Phase 1/2a study (NCT07223658) is sponsored by Arrowhead Pharmaceuticals official website and is ongoing. The lipid reduction figures cited represent mean maximal reductions from single-dose cohorts in interim topline data released September 15, 2026; multiple-dose data are expected to be presented at today’s AHA session.
ARO-DIMER-PA is an investigational drug from Arrowhead Pharmaceuticals that uses RNA interference (RNAi) to simultaneously silence two genes — PCSK9 and APOC3 — in liver cells. Silencing PCSK9 lowers LDL (“bad”) cholesterol; silencing APOC3 lowers triglycerides. It is in a NCT07223658 clinical trial registry and has not been approved by the FDA.
Inclisiran silences PCSK9 alone. Plozasiran silences APOC3 alone. ARO-DIMER-PA links both siRNA sequences in one molecular construct — meaning one injection addresses both lipid problems simultaneously, potentially replacing two separate drugs, two sets of insurance approvals, and two injection schedules with a single quarterly or semi-annual visit.
In single-dose cohorts, ARO-DIMER-PA produced mean maximal reductions of 72% in PCSK9 gene activity and 88% in APOC3 gene activity. Those knockdowns translated to downstream lipid reductions of 54% in LDL-cholesterol, 73% in triglycerides, 61% in non-HDL cholesterol, and 50% in ApoB. The safety profile through 400 mg single doses included injection-site reactions and headache as the most common adverse events; no drug-related serious adverse events were reported.
Mixed hyperlipidemia is a condition in which both LDL cholesterol and triglycerides are elevated simultaneously. It affects roughly 21% of US adults — an estimated 42 million people — and significantly raises the risk of heart attacks and strokes beyond what either elevated LDL or elevated triglycerides alone would cause. Current drugs address each problem separately but not both in a single agent.
No. Plozasiran (REDEMPLO) is already FDA-approved for familial chylomicronemia syndrome and silences APOC3 alone. ARO-DIMER-PA silences both PCSK9 and APOC3 simultaneously using a novel dimer molecular architecture. The two drugs share Arrowhead’s TRiM platform and GalNAc delivery technology, but they are chemically and clinically distinct.
ARO-DIMER-PA is in Phase 1/2a clinical development. Early-phase RNAi drugs that succeed in Phase 2 trials typically enter Phase 3 within 2 to 3 years, with FDA approval following an additional 2 to 3 years for the Phase 3 program. A realistic approval timeline, if all goes well, would be the late 2020s to early 2030s. Arrowhead has not announced a Phase 2 or Phase 3 timeline.